SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis ($AVNT.X) is trending with significant volume and community excitement, as traders discuss its potential as a major player in the crypto space. Community members are focused on holding, anticipating substantial gains and comparing it to other decentralized exchanges. The coin's association with notable investors like Peter Thiel and Pantera Capital is fueling further interest.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

HBAR.X is trending as the community discusses its potential for real-world applications and upcoming catalysts such as ETF possibilities. Comparisons to XRP and other crypto assets are frequent, with some traders strategizing around potential price movements. The coin's underlying technology and partnerships continue to be a central focus for investors.

PHUMPTOM (PHUM) is a meme token, the symbol of which is a phantom. The story of this character is built around trading, and according to legend, he was born on the pump platform.fun from the energy of green candles. Now it is a symbol of green charts, the keeper of green candles. His presence portends growth, and he brings good luck to traders.  A positive character who tells his story like an adventure, generates memes where he always rushes to the aid of traders and gives good luck to holders.

PHUMPTOM

PHUM.X is gaining attention as users share enthusiasm and encourage others to buy in early, touting it as the next potential "moon" shot. Much of the discussion revolves around its potential within the Phantom ecosystem, with community members actively monitoring charts and wallet activity. Several are coordinating efforts around the token and anticipate it will generate significant returns.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP.X is trending as the crypto community debates recent price action and potential market manipulation following news around ETF launches. Discussions range from disappointment with short-term performance to long-term bullish sentiment, with some traders eyeing key support levels and others expressing frustration. The focus remains on institutional adoption and regulatory clarity as potential catalysts.

"What's Updog?" is a Community Led token.

UpDog

UpDog ($UPDOG.X) is trending, and the community is actively engaging with the classic "What's UpDog?" joke, driving interest and curiosity. Built on Solana, the coin is focused on community and has the goal of being a top dog memecoin. The community highlights that it is listed on the Jupiter Strict List.

BlackBerry Ltd

BlackBerry ($BB.TSX) is trending amid discussions about its QNX technology powering various automotive and IoT systems, including NVIDIA's DRIVE AGX Thor. Community members highlight potential revenue growth from royalty backlogs and partnerships, with some speculating on a possible QNX spin-off or reverse merger. Overall, the conversation centers on BlackBerry's turnaround and future growth potential in cybersecurity and embedded systems.

Global Net Lease, Inc. is involved in real estate investment, acquiring a diversified global portfolio of commercial properties. It operates through the following segments: Industrial and Distribution, Multi-Tenant Retail, Single-Tenant Retail, and Office. The company was founded on July 13, 2011 and is headquartered in New York, NY.

Global Net Lease Inc

Global Net Lease ($GNL) is trending as investors discuss its high dividend yield and upcoming earnings report, while analysts adjust price targets and ratings. Community members are debating its valuation, strategic direction, and potential for growth amid discussions of acquisitions and dispositions. Some investors express concern about the sustainability of the dividend and potential value traps, while others see opportunity in its transformation and long-term lease agreements.

Flora Growth Corp. engages in the production of organic cannabis and pharmaceutical-grade medical products. It operates through the following segments: House of Brands and Commercial and Wholesale. The House of Brands segment includes multiple categories including food and beverage, nutraceuticals, cannabis accessories and technology, personal care and wellness. The Commercial and Wholesale segment includes distribution of pharmaceutical products to international markets. The company was founded on March 13, 2019 and is headquartered in Fort Lauderdale, FL.

Flora Growth Corp

FLGC is trending due to a recent $401 million funding announcement and a strategic shift towards AI, including a potential rebranding to ZeroStack, sparking community interest. Investors are actively discussing the company's new focus on AI-driven treasury strategies and the potential impact on the stock's valuation. Some are expressing skepticism around the company's association with cannabis, while others believe the move into AI and blockchain could present a significant opportunity.

Koma Inu, son of Shib and protector of BNB, is a dog themed token built around community driven decentralization and adoption.  Powered by pure meme energy, $KOMA is created for the community.  The cats had their time—now it's the dogs' turn to lead and make BSC memecoins great again! Our Team has a proven track record with meme tokens. Since the last bull run, we have successfully had multiple $100m+ projects.

Koma Inu

Koma Inu ($KOMA.X) is trending as the community discusses potential exchange listings and its association as the "protector of $BNB.X". Traders are actively discussing opportunities to "load up," with some drawing comparisons to other meme coins like $DOGE.X and $SHIB.X.

Gabelli Global Utility & Income Trust.

The Gabelli Global Utility & Income Trust

The Gabelli Global Utility & Income Trust is trending as investors assess its high-yield characteristics and exposure to the utility sector, while also considering its sensitivity to interest rates. Community members are actively discussing the fund's trading patterns near support levels and evaluating potential rally opportunities. Recent insider trading activity and continued monthly distributions are also key points of interest for investors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

Gilead Sciences (GILD) concluded the recent trading session at $113.59, signifying a +1.19% move from its prior day's close.

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Gilead Sciences (GILD) Ascends While Market Falls: Some Facts to Note

Gilead Sciences (GILD) reached $112.26 at the closing of the latest trading day, reflecting a +1.26% change compared to its last close.

Gilead Sciences (GILD) Exceeds Market Returns: Some Facts to Consider

In the latest trading session, Gilead Sciences (GILD) closed at $117.86, marking a +2.26% move from the previous day.

U.S. stocks closed Wednesday’s session mixed, with the broader S&amp;P 500 Index and the Nasdaq Composite hitting fresh highs, while the Dow Jones Industrial Average retreated.Although the tame producer price inflation report generated some strength in the market in the morning session, the perils of trading an overbought market made traders cautious as the session progressed.The following stocks saw the biggest volume surge in extended trading, even as the market turns its attention to the August consumer price inflation CPI) report due on Thursday:SLB Ltd. (SLB)After-hours move: 0.14%Trading volume: 5.86 millionOilfield services company SLB remained on investors’ radar despite the lack of any significant news. The Houston, Texas-based company’s shares rose over 1% on Wednesday, outperforming the broader market, after crude oil futures climbed 1.7% during the session.&nbsp;The stock, however, is down 3.5% for the year-to-date period.<figure class="image"><img style="aspect-ratio:618/54;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_11_at_12_40_24_AM_png_ff671b9818.webp" alt="Screenshot 2025-09-11 at 12.40.24 AM.png" width="618" height="54"><figcaption>SLB sentiment and message volume as of 12:40 a.m. ET, Sept. 11 | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment toward&nbsp;<a href="https://stocktwits.com/symbol/SLB">SLB stock</a> remained ‘neutral’ (51/100) by late Wednesday, and the message volume also stayed ‘normal.’Apple, Inc. (APPL)After-hours move: +0.10%Trading volume: 4.67 millionApple’s stock tumbled over 3% on Wednesday, even as the broader market managed to close in the green. The drop came despite the stock snagging a slew of price target hikes from Wall Street firms following the “Awe Dropping” hardware launch event held on Tuesday.BofA, Rosenblatt, Melius Research and Evercore ISI were among the firms that upped their price targets for Apple’s stock, with the updated estimates from these firms ranging from $241 to $290, the Fly reported. JPMorgan and Citi said the launch event was aligned with their expectations, while Morgan Stanley said it was slightly more awe-dropping than expectations.<a href="https://stocktwits.com/symbol/AAPL">Apple stock</a> is down about 9.1% year-to-date (YTD).<figure class="image"><img style="aspect-ratio:615/58;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_11_at_12_42_11_AM_png_38eba34d1f.webp" alt="Screenshot 2025-09-11 at 12.42.11 AM.png" width="615" height="58"><figcaption>AAPL sentiment and message volume as of 12:40 a.m. ET, Sept. 11 | source: Stocktwits</figcaption></figure>Retail sentiment toward the stock remained ‘extremely bullish’ (85/100), and the message volume was ‘extremely high.’&nbsp;Nvidia Corp. (NVDA)After-hours move: -0.10%Trading volume: 4.21 millionNvidia rode on the back of Oracle's (ORCL) exuberance and ended Wednesday’s session up nearly 5% at $177.33, although it was off its all-time intraday high of $184.48. However, retail interest is on the wane. On Stocktwits, retail sentiment toward&nbsp;<a href="https://stocktwits.com/symbol/NVDA">Nvidia stock</a> remained ‘bearish’ (37/100). The message volume on the stream was ‘low’ relative to historical norms.<figure class="image"><img style="aspect-ratio:622/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_11_at_12_43_57_AM_png_ec461b54d9.webp" alt="Screenshot 2025-09-11 at 12.43.57 AM.png" width="622" height="59"><figcaption>NVDA sentiment and message volume as of 12:40 a.m. ET, Sept. 11 | source: Stocktwits</figcaption></figure>The shares of the artificial intelligence chipmaker are up more than 32% this year.Merck &amp; Co. (MRK)After-hours move: +0.10%Trading volume: 3.91 millionPharma giant Merck has come onto investors’ radar as it declined on Wednesday, aligning with the pullback in the healthcare stocks in the afternoon. The S&amp;P 500 Healthcare Index fell 0.91% on Wednesday.The company also abandoned plans to build a research center in the U.K., citing the “challenges of the UK not making meaningful progress towards addressing the lack of investment in the life science industry and the overall undervaluation of innovative medicines and vaccines by successive UK governments,” the London Times&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.thetimes.com/business-money/companies/article/merck-attacks-uk-life-sciences-investment-scraps-1bn-hq-jbzz9nmnb">reported.</a><figure class="image"><img style="aspect-ratio:620/50;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_11_at_12_45_04_AM_png_6aeae81193.webp" alt="Screenshot 2025-09-11 at 12.45.04 AM.png" width="620" height="50"><figcaption>MRK sentiment and message volume as of 12:40 a.m. ET, Sept. 11 | source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/MRK">Merck stock</a>, which has fallen nearly 14% this year, elicited ‘bearish’ sentiment (42/100) from among users on Stocktwits. The message volume was at ‘normal’ levels.Gilead Sciences, Inc. (GILD)After-hours move: +0.65%Trading volume: 3.57 millionGildead Sciences was in the news on Wednesday as RBC Capital Markets named the company as one of the beneficiaries of Health and Human Services (HHS) Secretary and prominent antivaxxer Robert Kennedy's potential departure from the agency.&nbsp;The firm said healthcare could be viewed as "less unpredictable" and "more investable" if the secretary were to depart his position, according to the Fly.Kennedy has been under pressure from HHS employees, both former and current, to quit, as they alleged that he has put the health of America at risk with his actions, which include cancelling emergency use authorizations for COVID-19 vaccines without providing data or methods to justify the decision.<figure class="image"><img style="aspect-ratio:616/53;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_11_at_12_46_18_AM_png_9b7d1d480e.webp" alt="Screenshot 2025-09-11 at 12.46.18 AM.png" width="616" height="53"><figcaption>GILD sentiment and message volume as of 12:40 a.m. ET, Sept. 11 | source: Stocktwits</figcaption></figure>Retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/GILD">Gilead Sciences stock</a> remained ‘neutral’ (47/100). and the message volume also stayed at ‘normal’ levels.The stock has gained 26.5% YTD.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/goldman-sachs-ceo-sees-25-bps-fed-rate-cut-as-done-deal/chwN5NiRdH4">Will Fed Cut Rates Next Week? What Goldman Sachs CEO David Solomon Predicts For September Meeting And Rest Of 2025</a>

Traders work on the floor of the New York Stock Exchange (NYSE) on July 30, 2025, in New York City. 

SLB, Apple, Nvidia, Merck, Gilead Sciences: What Sparked Heavy After-Hours Trading In These 5 Stocks?

Two stocks, each from the tech and healthcare sectors, experienced brisk trading activity in the post-market session on Wednesday, although volumes were relatively muted.

Equity

Two stocks, each from the tech and healthcare sectors, experienced brisk trading activity in the post-market session on Wednesday, although volumes were relatively muted.


Novo Nordisk shares&nbsp;climbed 0.6% in&nbsp;early premarket trading on Wednesday after the world’s most valuable drugmaker announced plans to cut 9,000 jobs and forecast billions in annual savings, even as it lowered its profit outlook for the third time this year.The Danish firm behind blockbuster obesity drug Wegovy and diabetes treatment Ozempic said it would cut 9,000 positions, or about 11.5% of its 78,400-strong global workforce, as part of a company-wide transformation. About 5,000 roles will be eliminated in Denmark.The restructuring is expected to save 8 billion Danish crowns ($1.26 billion) annually by 2026 and will focus resources on diabetes and obesity, Novo’s key growth areas.&nbsp;“Our markets are evolving, particularly in obesity, as it has become more competitive and consumer-driven. Our company must evolve as well,” newly appointed Chief Executive Officer Mike Doustdar said in a statement.The overhaul is accompanied by one-off restructuring costs of 9 billion crowns in the third quarter, including impairment charges, which are partially offset by savings of 1 billion crowns in the fourth quarter.&nbsp;Novo now expects operating profit growth of 4%–10% this year at constant exchange rates, down from 10–16% forecast in August and as high as 27% projected in February.“Sometimes the hardest decisions are the right ones for the future we’re building,” Doustdar&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.linkedin.com/feed/update/urn:li:activity:7371410309493846016/">said in a LinkedIn post</a>. “This is the right thing to do for the long-term success of Novo Nordisk.”Novo has already frozen hiring for non-critical roles and withdrawn offers to some new hires.&nbsp;The shake-up follows a sharp slowdown in growth, with the company losing market share in the U.S. obesity market to Eli Lilly and facing pressure from compounding pharmacies that are allowed to make copycat versions of Wegovy due to supply shortages.The company, valued at about $650 billion at its peak last year, saw $70 billion wiped off its market capitalization in July after a profit warning and the appointment of Doustdar as CEO.Novo said it will report its nine-month results and provide a fresh outlook for 2025 on Nov. 5.On Stocktwits, retail sentiment for Novo Nordisk was ‘bearish’&nbsp;heading into Wednesday’s market open.<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk’s stock</a> has declined nearly 36% so far in 2025.($1=6.38 Danish krone)For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ozempic manufactured by Novo Nordisk packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on December 7, 2023. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Why Is Novo Nordisk’s Stock Rising Premarket Today?

The Danish drugmaker said an overhaul will save 8 billion crowns annually by 2026, but one-off restructuring costs will drag 2025 operating profit growth down to 4–10% from as much as 27% previously projected.

Shares of Xilio Therapeutics ended nearly 8% higher on Tuesday after the company reported positive early trial results for its cancer drug XTX301, began dosing patients in Phase 2, and secured a $17.5 million milestone payment from Gilead Sciences.Xilio said Phase 1 data for XTX301, a tumor-activated IL-12 therapy, showed anti-tumor activity in patients with advanced solid tumors, including two partial responses, while most side effects were mild or moderate.&nbsp;The treatment also sustained interferon gamma signaling across cycles, supporting the company’s approach of reprogramming “cold” tumors into inflamed “hot” ones.Based on the findings, Xilio selected a recommended Phase 2 dose and schedule and has begun treating patients in the Phase 2 portion of its ongoing Phase 1/2 trial in the U.S, which will enroll about 40 participants.&nbsp;Enrollment in Phase 1A has been completed, and Phase 1B expansion is still underway.The milestone payment from Gilead, tied to the start of Phase 2, extends Xilio’s cash runway into the first quarter of 2027. As of June 30, the company held $121.6 million in cash and equivalents and expects to receive the Gilead payment in the fourth quarter of 2025.Under their March 2024 global license agreement, Gilead may take over development and commercialization of XTX301 after reviewing clinical data, with an option fee of $75 million.&nbsp;Xilio could receive up to $500 million in additional development, regulatory and sales milestones, plus tiered royalties ranging from high single digits to mid-teens on global net sales.On Stocktwits, retail sentiment for Xilio was ‘bullish’ amid a 2,333% surge in 24-hour message volume.One user said that the stock had “solid news” but needed more trading volume to push through the $0.80 level.<stembedurl>https://stocktwits.com/MrTicker/message/627979369</stembedurl>Another user predicted the shares would climb quickly, noting it was “super hard to get shares.”&nbsp;They highlighted that Xilio held about $140 million in cash against a roughly $38 million market cap, arguing the market had assigned little to no value to its partnerships, assets, or even its cash balance, and suggesting a reprice was likely.<stembedurl>https://stocktwits.com/SteadyTrade55/message/627979366</stembedurl><a href="https://stocktwits.com/symbol/XLO">Xilio’s stock</a> has declined 21.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 Xilio’s stock has declined 21.5% so far in 2025. (Photo credit: Getty Images)

Xilio Stock Jumps 8% On Cancer Drug Data; Gilead Boost Extends Cash Runway Into 2027 — Retail Says Stock Undervalued

The company has begun dosing patients in Phase 2 of its trial for XTX301, a tumor-activated IL-12 therapy that showed two partial responses in early testing and was generally well tolerated.

U.S. stocks reversed course on Monday, although trading was characterized by volatility amid the uncertainties that continue to abound. IT and consumer discretionary gained some ground, helping to offset the weakness or sluggish performances of most other sectors.Nevertheless, the Nasdaq Composite Index hit an all-time intraday and closing high.Even as the market deals with the uncertainty around the Federal Reserve’s next rate move, the following stocks saw substantial trading volume in the after-hours:Wolfspeed, Inc. (WOLF)After-hours move: +57.73%Trading volume: 26.43 millionThe increased trading volume in&nbsp;<a href="https://stocktwits.com/symbol/WOLF">Wolfspeed stock</a> was accompanied by an after-hours jump in the shares of the company, which manufactures wide-bandgap semiconductors, focusing on silicon carbide and gallium nitride materials.Wolfspeed&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-wolfspeed-stock-skyrocketed-60-in-today-s-after-hours/chw0o5yRdrH">said</a> Monday after the market close that the company has received Court approval of its Plan of Reorganization, and it is slated to file a Chapter 11 bankruptcy protection&nbsp;claim over the next several weeks.Retail users of Stocktwits cheered the development, with sentiment toward Wolfspeed stock improving to ‘extremely bullish’ levels (86/100) by late Monday from ‘neutral’ a day ago. The message volume on the stream picked up pace to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:619/53;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_09_at_2_18_46_AM_png_298850cc70.webp" alt="Screenshot 2025-09-09 at 2.18.46 AM.png" width="619" height="53"><figcaption>WOLF sentiment and message volume as of 2:15 a.m. ET, Sept. 9 | source: Stocktwits</figcaption></figure>Wolfspeed stock has lost over 81% year-to-date (YTD).Nvidia Corp. (NVDA)After-hours move: -0.07%Trading volume: 6.99 million<a href="https://stocktwits.com/symbol/NVDA">Nvidia’s stock</a> rose 0.77% on Monday despite an analyst’s price target cut. Citi analyst Atif Malik reduced the price target for the stock to $200 from $210 and maintained a ‘Buy’ rating, the Fly reported. The analyst attributed his tempered opinion to Broadcom’s (AVGO) comments concerning the strong growth of its artificial intelligence (AI) chips. As such, he reduced his 2026 GPU sales estimate for Nvidia by 4%.The research firm expects a $12 billion hit to Nvidia's GPU sales from Broadcom’s XPU deals.On Monday, the Jensen Huang-led company also voiced its opinion about the GAINS AI Act, which was proposed by U.S. Senators last week to regulate AI GPU shipments to adversaries. The company reiterated that the U.S. will always be its primary market but lashed out at the bill. “While it may have good intentions, this bill is just another variation of the AI Diffusion Rule and would have similar effects on American leadership and the U.S. economy,” it said.After the market closed, Nvidia filed with a 144 statement with the SEC regarding Huang’s intention to sell 75,000 shares. It also filed a Form 4, communicating the sale of 225,000 Nvidia shares last Thursday following the exercise of options.Retail sentiment toward Nvidia’s stock stayed ‘bearish’ (32/100) and the message volume was at ‘low’ levels.<figure class="image"><img style="aspect-ratio:613/52;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_09_at_2_17_03_AM_png_06ec1e9d12.webp" alt="Screenshot 2025-09-09 at 2.17.03 AM.png" width="613" height="52"><figcaption>NVDA sentiment and message volume as of 2:15 a.m. ET, Sept. 9 | source: Stocktwits</figcaption></figure>The stock has gained 25% year-to-date.Gilead Sciences, Inc. (GILD)After-hours move: unchangedTrading volume: 6.97 millionThe increased trader interest in&nbsp;<a href="https://stocktwits.com/symbol/GILD">Gilead stock</a> was despite the lack of any meaningful, fresh catalysts. Last Friday, the company announced a partnership with the U.S. State Department and the United States President’s Emergency Plan for AIDS Relief (PEPFAR) to deliver lenacapavir, its twice-yearly injectable HIV-1 capsid inhibitor, for the prevention of HIV as pre-exposure prophylaxis (PrEP).&nbsp;It also broke ground at the new Pharmaceutical Development and Manufacturing (PDM) Technical Development Center (NTDC) at the company’s Foster City, California headquarters. This is part of the company’s proposed $32 billion investment in the U.S. through 2030.On Stocktwits, retail sentiment toward Gilead stock tempered to ‘neutral’ (54/100) from ‘bullish’ a day ago. The message volume remained ‘low.’<figure class="image"><img style="aspect-ratio:619/56;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_09_at_2_21_10_AM_png_6d02c5f0f3.webp" alt="Screenshot 2025-09-09 at 2.21.10 AM.png" width="619" height="56"><figcaption>GILD sentiment and message volume as of 2:15 a.m. ET, Sept. 9 | source: Stocktwits</figcaption></figure>The shares are up over 27% YTD.SLB Ltd. (SLB)After-hours move: unchangedTrading volume: 6.59 millionOilfield services company SLB was on investors’ radar amid the ongoing volatility in oil prices.&nbsp;<a href="https://stocktwits.com/symbol/SLB">SLB stock</a>, which is down 4.5% this year, drew ‘bullish’ sentiment (59/100) from retailer users of Stocktwits, up from ‘neutral’ a day ago. The message volume remained at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:624/58;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_09_at_2_20_08_AM_png_cff58953a4.webp" alt="Screenshot 2025-09-09 at 2.20.08 AM.png" width="624" height="58"><figcaption>SLB sentiment and message volume as of 2:15 a.m. ET, Sept. 9 | source: Stocktwits</figcaption></figure>Corning, Inc. (GLW)After-hours move: +0.25%Trading volume: 5.92 millionNew York-based Corning, a maker of optical fibers and cables, and hardware and equipment products, has seen its shares rise over 54% this year.&nbsp;The stock may have evinced interest ahead of Apple’s iPhone 17 launch event scheduled for Tuesday. In early August, Apple announced a new $2.5 billion commitment to produce all of the cover glass for iPhone and Apple Watch in Corning’s Harrodsburg, Kentucky, manufacturing facility.<figure class="image"><img style="aspect-ratio:622/54;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_09_at_2_22_20_AM_png_fa0c45fe3b.webp" alt="Screenshot 2025-09-09 at 2.22.20 AM.png" width="622" height="54"><figcaption>GLW sentiment and message volume as of 2:15 a.m. ET, Sept. 9 | source: Stocktwits</figcaption></figure>Retail sentiment toward&nbsp;<a href="https://stocktwits.com/symbol/GLW">Corning stock</a> has remained ‘neutral’ (49/100) and the message volume stayed ‘high.’For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/peter-schiff-warns-getting-out-of-dollar-as-it-wallows-near-7-week-low/chw0sQWRdsc">&nbsp;‘Get Out Of US Dollar Before It’s Too Late,’ Says Peter Schiff As Greenback Wallows Near 7-Week Low: Spotlight Shifts To BLS Annual Revision</a>

Wolfspeed, Nvidia, Gilead, SLB, Corning: What Sparked Heavy After-Hours Trading In These 5 Stocks?

On Monday, the tech-heavy Nasdaq Composite climbed to a new high despite the ongoing uncertainty regarding the state of the U.S. economy and the rate outlook.

Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock

GILD Wins Approval for Twice-Yearly HIV Prevention Shot in the EU

Gilead secures EU approval for twice-yearly HIV prevention shot Yeytuo, backed by strong trial data and expanded market protection.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

GILD
Gilead Sciences, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest GILD News

GILD Gilead Sciences, Inc.